293 related articles for article (PubMed ID: 35112331)
1. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.
Huang M; Haiderali A; Fox GE; Frederickson A; Cortes J; Fasching PA; O'Shaughnessy J
Pharmacoeconomics; 2022 May; 40(5):519-558. PubMed ID: 35112331
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
[TBL] [Abstract][Full Text] [Related]
3. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.
Sieluk J; Song Y; Freimark J; Huang M; Haiderali A; Berman R; Wang T; Signorovitch J; Hirshfield KM
Adv Ther; 2022 Feb; 39(2):943-958. PubMed ID: 34918193
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
5. The humanistic and economic burden of systemic lupus erythematosus : a systematic review.
Meacock R; Dale N; Harrison MJ
Pharmacoeconomics; 2013 Jan; 31(1):49-61. PubMed ID: 23329592
[TBL] [Abstract][Full Text] [Related]
6. A systematic literature review on direct and indirect costs of triple-negative breast cancer.
Rezaei S; Babaei M
Cost Eff Resour Alloc; 2023 Nov; 21(1):92. PubMed ID: 38037138
[TBL] [Abstract][Full Text] [Related]
7. Economic and Humanistic Burden of Cerebral Vasospasm and Its Related Complications after Aneurysmal Subarachnoid Hemorrhage: A Systematic Literature Review.
Thompson JC; Chalet FX; Manalastas EJ; Hawkins N; Sarri G; Talbot DA
Neurol Ther; 2022 Jun; 11(2):597-620. PubMed ID: 35441974
[TBL] [Abstract][Full Text] [Related]
8. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.
Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C
Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. A systematic literature review on the health-related quality of life and economic burden of Fabry disease.
Jovanovic A; Miller-Hodges E; Castriota F; Takyar S; Howitt H; Ayodele O
Orphanet J Rare Dis; 2024 Apr; 19(1):181. PubMed ID: 38689282
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease.
Srivastava K; Thakur D; Sharma S; Punekar YS
Pharmacoeconomics; 2015 May; 33(5):467-88. PubMed ID: 25663178
[TBL] [Abstract][Full Text] [Related]
12. Clinical, economic, and humanistic burden of asthma in Canada: a systematic review.
Ismaila AS; Sayani AP; Marin M; Su Z
BMC Pulm Med; 2013 Dec; 13():70. PubMed ID: 24304726
[TBL] [Abstract][Full Text] [Related]
13. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Cancer Med; 2020 Oct; 9(20):7548-7557. PubMed ID: 32862501
[TBL] [Abstract][Full Text] [Related]
14. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.
Franklin M; Pollard D; Sah J; Rayner A; Sun Y; Dube F; Sutton A; Qin L
Adv Ther; 2024 Jun; ():. PubMed ID: 38833143
[TBL] [Abstract][Full Text] [Related]
15. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of the Economic and Humanistic Burden of Gout.
Shields GE; Beard SM
Pharmacoeconomics; 2015 Oct; 33(10):1029-47. PubMed ID: 25969152
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
[TBL] [Abstract][Full Text] [Related]
18. Humanistic and cost burden of systemic sclerosis: A review of the literature.
Fischer A; Zimovetz E; Ling C; Esser D; Schoof N
Autoimmun Rev; 2017 Nov; 16(11):1147-1154. PubMed ID: 28899803
[TBL] [Abstract][Full Text] [Related]
19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
20. Humanistic and economic burden of depression and anxiety among adults with migraine: A systematic review.
Alwhaibi M; Alhawassi TM
Depress Anxiety; 2020 Nov; 37(11):1146-1159. PubMed ID: 32579794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
